ArticleDiabetologia2006
Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes.
Article in Diabetologia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 1 synthesis or guideline pooled it, 306 citations in OpenAlex.
- Therapeutic role of interleukin-1 receptor antagonist in pancreatic diseases: mendelian randomization study.Frontiers in immunology · 2023Pooled it
- Assessment of immune function in individuals without and with obesity and normoglycemia, glucose intolerance, or type 2 diabetes: primary findings of the NutrIMM study, a single-arm controlled feeding trial.The American journal of clinical nutrition · 2025Trial
- Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients.Journal of nephrology · 2014Trial
- Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans.Diabetes · 2013Trial
- Microplastics and Nanoplastics in Food: Dietary Toxicology Beyond Particle Counts.Comprehensive reviews in food science and food safety · 2026Review
- Integrated analysis of insulin resistance reveals metabolic remodeling following diet switch-triggered calorie reduction.Science advances · 2026Article
- Long-Chain n-3 Polyunsaturated Fatty Acids Attenuate the Severity of Obesity-Associated White Adipose Tissue and Skeletal Muscle Dysfunction.Marine drugs · 2026Review
- Oxidized metabolites of linoleic acid as biomarkers of pancreatic beta-cell function in the first-onset type 2 diabetic patients with obesity.Journal of endocrinological investigation · 2026Article
- Obesity and type 2 diabetes as chronic inflammation: how does the cytokine evidence align?Frontiers in endocrinology · 2026Review
- IL-1 family cytokines in inflammation and immunity.Cellular & molecular immunology · 2025Review
- Article
- Article
- Myeloperoxidase impacts vascular function by altering perivascular adipocytes' secretome and phenotype in obesity.Cell reports. Medicine · 2025Article
- Article
- Adiponectin and Adiponectin Receptors in Atherosclerosis.Endocrine reviews · 2025Review
- Eye on the horizon: The metabolic landscape of the RPE in aging and disease.Progress in retinal and eye research · 2025Review
- Impaired suppression of fatty acid release by insulin is a strong predictor of reduced whole-body insulin-mediated glucose uptake and skeletal muscle insulin receptor activation.Acta physiologica (Oxford, England) · 2025Article
- An improvedAdipocyte · 2024Article
- Blocking interleukin-1 receptor type 1 (IL-1R1) signaling in hepatocytes slows down diethylnitrosamine-induced liver tumor growth in obese mice.Hepatology communications · 2024Article
- IL-1β promotes adipogenesis by directly targeting adipocyte precursors.Nature communications · 2024Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisAdipose tissue inflammation has recently been implicated in the pathogenesis of insulin resistance and is probably linked to high local levels of cytokines. IL1B, a proinflammatory cytokine, may participate in this alteration. MATERIALS AND
methodsWe evaluated the chronic effect (1-10 days) of IL1B (0.1-20 ng/ml) on insulin signalling in differentiating 3T3-F442A and differentiated 3T3-L1 murine adipocytes and in human adipocytes. We also assessed expression of the gene encoding IL1B in adipose tissue of wild-type and insulin-resistant mice (diet-induced and genetically obese ob/ob mice).
resultsIL1B inhibited insulin-induced phosphorylation of the insulin receptor beta subunit, insulin receptor substrate 1, Akt/protein kinase B and extracellular regulated kinase 1/2 in murine and human adipocytes. Accordingly, IL1B suppressed insulin-induced glucose transport and lipogenesis. Long-term treatment of adipose cells with IL1B decreased cellular lipid content. This could result from enhanced lipolysis and/or decreased expression of genes involved in lipid metabolism (acetyl-CoA carboxylase, fatty acid synthase). Down-regulation of peroxisome proliferating-activated receptor gamma and CCAAT/enhancer-binding protein alpha in response to IL1B may have contributed to the altered phenotype of IL1B-treated adipocytes. Moreover, IL1B altered adipocyte differentiation status in long-term cultures. IL1B also decreased the production of adiponectin, an adipocyte-specific protein that plays a positive role in insulin sensitivity. Expression of the gene encoding IL1B was increased in epididymal adipose tissue of obese insulin-resistant mice. CONCLUSIONS/
interpretationIL1B is upregulated in adipose tissue of obese and insulin-resistant mouse models and may play an important role in the development of insulin resistance in murine and human adipose cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.